RED公司的发展战略研究

华中科技大学硕士学位论文RED公司的发展战略研究姓名：夏南申请学位级别：硕士专业：工商管理指导教师：聂鸣20060425IIIREDRED19981999REDpH4IVIG(HBIG)(TIG)(RIG)REDREDREDIVAbstractStartingfrom1990s,theplasmaproteintherapeuticsindustry,beinganimportantindustrialtypeofthebiopharmaceuticalfield,hassteppedintoarapiddevelopmentperiodinourcountry.Manymanufacturersofplasma-derivedproductsgainednoticeableprofit.5yearsago,theseenterprisesbeguntomeettheirhardtimebecauseofthekeencompetition.Thisresearchisaboutamiddle-scalelimitedcorporation(simplyas“RED”),whichisabiologicalproductsmanufacturer,engagedinproducing,marketingandresearching.Thecorporationcanprovideseveralkindsofproducts,includingHumanAlbumin,HumanImmunoglobulin,HumanImmunoglobulinforIntravenousInjection(pH4),HumanHepatitisBImmunoglobulin,HumanTetanusImmunoglobulin,andHumanRabiesImmunoglobulin,etc.ThedissertationstartswiththebackgroundoftheplasmaproteintherapeuticindustryandformulatesthedifficultyandopportunityforRED’sdevelopment.Aftergivingthemissionstatement,thepaperanalysesthecompetitionenvironmentofREDbyusingtheIndustrialOrganizationalStructureTheoryandforecaststhedevelopmentoftheplasmaproteintherapeuticsindustry.OnthebaseoftheEnterpriseResourceTheoryweevaluatetheenterpriseresourceandcapability.AtlastwechoosethecostleadershipstrategyasthebaseofcorporatestrategyforREDandmakesomesuggestionsonitsdevelopment.KeyWords:BloodproductStrategicanalysisStrategicchoice111.11796200208091%~92%(6.5%~7.5%)55%~60%(0.75%)8%~9%(0.7%)(0.15%)99%(40%~45%)1-11-1291%~926.5~7.5[1]3123CohnpH[2]~[5]11[1][6]31-1[6]FEIBAVIII1-1-ATAT-IIIAT-IIICMVIXVIIIVIIIIgMRhDRh120075900955738150080405AventisBehringBaxterBayerAlphaRD10HIV460101985FDAAIDS[3][4][5][7][8]1.219198030205066080198920052005711997119981231GMP5199612581995CohnpH1997GMP1-2100[8]6l2200512GMP[9]3141112111123347IgGFCVIII1.3[10]1200512GMP34[8]734120150802150300500232004193.238533~474GMP2002019955797382001-2005[11]5GMP9619962684113823.821.950.324%7815%1WTO121[12]10210~20[13]345WTO1122.1.208012overallcostleadershipdifferentiationfocus13[14]~[25]2.2199014[14]~[25]2.315[14]~[25]162-1REDSWOT173RED3.1REDmissionstatement[26][27]RED1customers2productsorservices3markets4technology185concernforsurvivalgrowthandprofitability6philosophy7self-concept8concernforpublicimage9concernforemployeesRED3.23.2.1PEST12119212010[28]120108000250330430245106199920004020007020200061571040~50160GMPGSPGAPGLP3131984917AIDS20003020012005[11]21199820102005101101~l5122001320014562001200222720045156352004[18]2107%~8%201068007200[29]197819982017.5200544002006510017%7[30]2010“”2320101100300~500200~300202010~2012:3:(4):10(5):(6):1400(7):24[31]DNAWTO253[32]200020000~142897922.89%15648879370.156588116.9619900144.865l.3920053l50311953196419821990200020055943569458100818113368126583130756307993565251944584956535567375286363380648874548736122863381107.56105.46106.3106.6106.74106.300~1436.2840.6933.5927.6922.8920.2715~6459.3155.7561.566.7470.1572.04%654.413.564.915.576.967.69200520057.526l.520106.027.046.2453.76%20057.514.71978199727773.72820007928916047198520033-23-320038472.202622.24475.98115.757.315.9632199520002001200220033537.574998.005309.016030.006510.94110.11318.07343.28429.94475.983.116.366.477.137.312733199520002001200220031310.361670.131741.091834.001943.3042.4887.5796.61103.99115.753.245.245.555.675.964[33]501997863283.2.23l[17][34]3111AB[16][20]292GMP20001.9400080004~631996[35]199642001GMPGMP30567231312GSP34122004630%902005-20062005200421/20%~30%2005326-2932/200690302006[36]32006512005200520002004170/10g2005220-250/10g250/10g2GMP3334504030620600161600185600556002007[38]3.2.3RED323412123-235RED3.2.4RED1[39]2070209057001500150300800216363PCR43.3RED3.3.1[40]33373-3RED3.3.238RED1GMP5300822RED1177463%RED3RED34RED39REDRED45RED6000RED6REDRED3.3.340[14][21][39]RED1GMPRED0.1600RED2[24]341U3.4REDSWOTREDSWOT112000220037.3159634245GMP199558199530006782134GMP234345WTO67831RED2RED3RED4445RED6RED41RED2RED3RED456RED4544.1REDREDRED[14][21][39]REDRED46REDRED414-1RED3REDRED120052050ml1995315200120024483304734GMP50005801201506REDRED1RED2RED3VIIIRED484REDRED5REDREDRED4.2RED4-2REDRED198520001512RED4-2RED,REDRED49424.2.1RED20[36]REDREDREDI1.2.3.4.5.6.7.III1.2.3.4.5.6.IV1.2.3.4.II1.2.3.4.5.6.50REDREDRED4.2.2RED4-34351REDVIIIVIIIWFH403/4102001010010REDREDREDRED52REDGMPWHOGMPEUGMPFDAGMPRED4.2.34-3REDRED534.34.3.1REDREDREDREDREDRED544.3.2901020906200024132020002060-70[40]1008025509061989BMSquibbBMS199419962000LaxosmithKline115020055RDRDRDREDREDREDREDREDREDRED56123RED44.3.3[41]WTO571234RED1234RED58REDWTOREDRED59JoelRossMichaelKamiRED60RED61[1]..2.:,1993.53~109[2]T.Burnouf,M.Radosevich.Reducingtheriskofinfectionfromplasmaproducts:specificpreventativestrategies.BloodRev,2000,14:94~96[3]T.Burnouf,A.Padilla,C.Schaerer,etal.RecommendationsfortheProduction,ControlandRegulationofHumanPlasmaforFractionation.In:T.Burnouf,A.Padilla,C.Schaerer.theWHOTechnicalReportSeries(2005).Geneva:WHO,2005.Annex4[4]B.Horowitz,P.Minor,J.J.morgenthaler.GuidelinesonViralInactivationandRemovalProceduresIntendedtoAssuretheViralSafetyofHumanBloodPlasmaProducts.In:B.Horowit